These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38800847)

  • 1. Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
    Dafer RM; Tietjen GE; Rothrock JF; Vann RE; Shrewsbury SB; Aurora SK
    Headache; 2024 Sep; 64(8):983-994. PubMed ID: 38800847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
    Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
    Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD
    Smith TR; Winner P; Aurora SK; Jeleva M; Hocevar-Trnka J; Shrewsbury SB
    Headache; 2021 Sep; 61(8):1214-1226. PubMed ID: 34363701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INP104: a drug evaluation of a nonoral product for the acute treatment of migraine.
    Starling AJ; Mallick-Searle T; Shrewsbury SB; Aurora SK
    Pain Manag; 2023 May; 13(5):283-298. PubMed ID: 37337861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.
    Cooper W; Ray S; Aurora SK; Shrewsbury SB; Fuller C; Davies G; Hoekman J
    J Aerosol Med Pulm Drug Deliv; 2022 Dec; 35(6):321-332. PubMed ID: 36108289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
    Lipton RB; Albrecht D; Bermudez M; Hu J; Hussey E; Levy J
    Headache; 2024 Mar; 64(3):266-275. PubMed ID: 38413540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.
    Noveck RJ; Douglas PS; Chow SC; Mangum B; Kori S; Kellerman DJ
    Drug Des Devel Ther; 2013; 7():619-25. PubMed ID: 23926420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
    Bodie S; Curran AK; Gonzalez-Nelson AC; Perry JM; Manning DC; Wasilewski MM
    Headache; 2024 Jun; 64(6):643-651. PubMed ID: 38717120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
    Silvestro M; Orologio I; Tessitore A; Trojsi F; Tedeschi G; Russo A
    Expert Rev Neurother; 2024 Jun; 24(6):555-564. PubMed ID: 38655598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.
    Tepper SJ; Albrecht D; Ailani J; Kirby L; Strom S; Rapoport AM
    CNS Drugs; 2024 Dec; 38(12):1017-1027. PubMed ID: 39373843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
    Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
    Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
    Saper JR; Silberstein S
    Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.